cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3535/d50-eea-t65
title: Coluzea eastwoodae (Kilburn, 1971)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/p1y-dyc-gnq
title: Marmorofusus verrucosus (Gmelin, 1791)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/60g-92e-fd2
title: Oliva tremulina Lamarck, 1811

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/kxx-txk-eqt
title: Oliva fulgurator (Röding, 1798)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.6084/m9.figshare.29924012
title: Supplementary Material for: Familial Hyperekplexia Caused by a Novel Homozygous SLC6A5 Variant: Case Report

description: Introduction: Hyperekplexia is a rare non-epileptic paroxysmal disorder characterized by a marked startle response and hypertonia to auditory, tactile, or visual sudden external stimuli. GLRA1, SLC6A5, GLRB, and ATAD1 gene pathogenic variants have been identified in these patients.

Case Report: The girl was born 39+1 weeks and admitted to the neonatal intensive care unit with spasm-like contractions and followed by breath holding. Except for transient hyperammonemia, neurologic and metabolic tests were normal, and there was no seizure-like movement during hospi-talization. In the 4th month of her life, the patient had spasm-like findings with stimulation, and the symptoms were controlled with clonazepam, considering hyperexplexia. Clinical exome se-quencing revealed a previously undescribed homozygous variant [c.748T&gt;C; p.(Ser250Pro) in exon 4] in the SLC6A5 (NM_004211.5) gene. Sanger sequencing confirmed the c.748T&gt;C variant in the family: both parents were heterozygous carriers, while the brother was homozygous. Her sibling also had stimulus-induced crying and stiffness in infancy, but these resolved within months without treatment, and his developmental milestones have been age-appropriate. 

Conclusions: This case highlights the importance of recognizing hereditary hyperekplexia in the differential diagnosis of neonatal seizures and supports the potential pathogenic relevance of the SLC6A5 c.748T&gt;C (p.Ser250Pro) variant, particularly in benign, non-recurrent cases with transient hyperammonemia from catabolic stress and glycine transporter dysfunction.
DOI: 10.6084/m9.figshare.29924012.v1
title: Supplementary Material for: Familial Hyperekplexia Caused by a Novel Homozygous SLC6A5 Variant: Case Report

description: Introduction: Hyperekplexia is a rare non-epileptic paroxysmal disorder characterized by a marked startle response and hypertonia to auditory, tactile, or visual sudden external stimuli. GLRA1, SLC6A5, GLRB, and ATAD1 gene pathogenic variants have been identified in these patients.

Case Report: The girl was born 39+1 weeks and admitted to the neonatal intensive care unit with spasm-like contractions and followed by breath holding. Except for transient hyperammonemia, neurologic and metabolic tests were normal, and there was no seizure-like movement during hospi-talization. In the 4th month of her life, the patient had spasm-like findings with stimulation, and the symptoms were controlled with clonazepam, considering hyperexplexia. Clinical exome se-quencing revealed a previously undescribed homozygous variant [c.748T&gt;C; p.(Ser250Pro) in exon 4] in the SLC6A5 (NM_004211.5) gene. Sanger sequencing confirmed the c.748T&gt;C variant in the family: both parents were heterozygous carriers, while the brother was homozygous. Her sibling also had stimulus-induced crying and stiffness in infancy, but these resolved within months without treatment, and his developmental milestones have been age-appropriate. 

Conclusions: This case highlights the importance of recognizing hereditary hyperekplexia in the differential diagnosis of neonatal seizures and supports the potential pathogenic relevance of the SLC6A5 c.748T&gt;C (p.Ser250Pro) variant, particularly in benign, non-recurrent cases with transient hyperammonemia from catabolic stress and glycine transporter dysfunction.
DOI: 10.3535/5zf-z95-tvy
title: Parvamussium fenestratum (Forbes, 1844)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/xtm-zht-fke
title: Conus textile Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/a20-z1r-93g
title: Turridae H. Adams & A. Adams, 1853 (1838)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/ynv-qlm-myk
title: Nassarius particeps (Hedley, 1915)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/5a4-v3z-dbl
title: Daphnella Hinds, 1844

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/2xk-p5p-3rj
title: Mitrella broderipii (G. B. Sowerby I, 1844)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/vst-x1w-b6v
title: Nassarius consensus (Ravenel, 1861)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/1mt-q98-bjk
title: Vexillum vulpecula (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/bjg-bkc-8r6
title: Nassarius micans (A. Adams, 1852)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.6084/m9.figshare.29924018
title: Supplementary Material for: Real-world Dose Escalation and Associated Direct Costs of Biologics in Management of Ulcerative Colitis: A Retrospective Database Study

description: Introduction: Dose escalation with biologics is common among patients with ulcerative colitis (UC). We investigated the dose escalation and associated incremental costs among patients treated with biologics for UC.
Methods: This study utilized the Merative™ MarketScan® database in the United States (US) to identify adults with at least two claims for UC and at least two refill/infusion claims for maintenance doses of biologics (including adalimumab, infliximab, ustekinumab, and vedolizumab) from January 1, 2015, through December 31, 2022. Patients were stratified by the presence (bio-experienced) or absence (bio-naïve) of other advanced therapy claims during the baseline period (12 months before index date). Descriptive statistics were used to summarize the dose escalation measures (frequency and magnitude of dose escalation, incremental cost due to dose escalation, and time-to-first dose escalation).
Results: Of 1,812 patients with UC who were on biologics during the maintenance phase, 56.3% had dose escalation. Overall, magnitude of dose escalation was 119.9% adalimumab, 34.9% infliximab, 81.6% ustekinumab, and 55.4% vedolizumab. Overall, median time-to-first dose escalation after initiating maintenance therapy ranged from nearly a month to 5 months (adalimumab: 0.8, infliximab: 5.1, ustekinumab: 1.3, and vedolizumab: 5.1). Estimated incremental annual cost per patient incurred due to dose escalation in US dollars was $37,359 for adalimumab (bio-naïve: $36,367; bio-experienced: $44,180) and $73,765 for ustekinumab (bio-naïve: $74,554; bio-experienced: $73,599).
Conclusions: Dose escalation with biologics for UC in the US is common. This practice has substantially increased the average medication cost of biologics to payers/patients compared to their approved doses.
DOI: 10.6084/m9.figshare.29924018.v1
title: Supplementary Material for: Real-world Dose Escalation and Associated Direct Costs of Biologics in Management of Ulcerative Colitis: A Retrospective Database Study

description: Introduction: Dose escalation with biologics is common among patients with ulcerative colitis (UC). We investigated the dose escalation and associated incremental costs among patients treated with biologics for UC.
Methods: This study utilized the Merative™ MarketScan® database in the United States (US) to identify adults with at least two claims for UC and at least two refill/infusion claims for maintenance doses of biologics (including adalimumab, infliximab, ustekinumab, and vedolizumab) from January 1, 2015, through December 31, 2022. Patients were stratified by the presence (bio-experienced) or absence (bio-naïve) of other advanced therapy claims during the baseline period (12 months before index date). Descriptive statistics were used to summarize the dose escalation measures (frequency and magnitude of dose escalation, incremental cost due to dose escalation, and time-to-first dose escalation).
Results: Of 1,812 patients with UC who were on biologics during the maintenance phase, 56.3% had dose escalation. Overall, magnitude of dose escalation was 119.9% adalimumab, 34.9% infliximab, 81.6% ustekinumab, and 55.4% vedolizumab. Overall, median time-to-first dose escalation after initiating maintenance therapy ranged from nearly a month to 5 months (adalimumab: 0.8, infliximab: 5.1, ustekinumab: 1.3, and vedolizumab: 5.1). Estimated incremental annual cost per patient incurred due to dose escalation in US dollars was $37,359 for adalimumab (bio-naïve: $36,367; bio-experienced: $44,180) and $73,765 for ustekinumab (bio-naïve: $74,554; bio-experienced: $73,599).
Conclusions: Dose escalation with biologics for UC in the US is common. This practice has substantially increased the average medication cost of biologics to payers/patients compared to their approved doses.
DOI: 10.15468/dl.x8nrjk
title: Occurrence Download

description: A dataset containing 433 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Polygonatum punctatum"
 ]
}

 The dataset includes 433 records from 42 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0010911-250811113504898/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.3535/6xx-rg6-awf
title: Zospeum troglobalcanicum Absolon, 1916

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/vgn-76p-zxh
title: Volutella muricata (Born, 1778)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/2fw-8wg-scc
title: Volvarina avena (Kiener, 1834)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/9tr-6vf-wp6
title: Cymbiola vespertilio (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.6084/m9.figshare.29924021
title: Supplementary Material for: Team Based Pediatric Type 1 Diabetes Care in the US: Current Practices and Sustainability Concerns

description: Introduction: Multidisciplinary care can improve glycemic outcomes in individuals with type 1 diabetes (T1D). Yet, prior studies suggest limited utilization of team-based care and either no reimbursement or inadequate reimbursement for diabetes and nutritional education, mental health and social support as well as remote services. We sought to evaluate multidisciplinary care services offered by pediatric diabetes centers to understand whether current practices are sustainable. Methods: The Pediatric Endocrine Society Diabetes Special Interest Group collaborated with the T1DX- Quality Improvement Collaborative to survey US pediatric diabetes centers on care delivery practices and resources for new onset and ongoing care, introduction of technology and telehealth focusing on team-based approaches. Results: We analyzed responses from 31 centers, mostly academic, from 16 states and Washington DC representing all geographical regions providing care for 45,759 youth with T1D who had at least one visit in 2022. Most centers (74%) provided initial diabetes education in the inpatient setting using clinic-employed staff. The majority initiated CGMs at or close to diagnosis and offered insulin pump therapy within the first year. All but one center encouraged communication with diabetes teams between visits. Less than half of practices estimated that at least 50% of their youth with T1D received mental health services and assessments for social concerns annually. Telehealth was utilized by all centers. Many centers indicated suboptimal reimbursement, and 87% operated at a budget deficit. Discussion: Despite the commitment of pediatric diabetes centers to provide high quality multidisciplinary care, many youth with T1D may not receive the services as frequently as recommended. These services are often unreimbursed. We advocate for alternative reimbursement models for clinical workflows that support the delivery of individualized, multidisciplinary care aligned with best practices shown to improve clinical outcomes and quality of life for youth with T1D. Examples include expansion of telemedicine and remote monitoring, non-face-to-face acute and routine care, navigation of technology, supplies and services, engagement and coordination of community-based resources among others. Such models would promote equitable, needs-based care while enabling centers to operate efficiently.
DOI: 10.3535/96a-mmq-2pd
title: Lasaea rubra (Montagu, 1803)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/d30-h1v-r55
title: Sinistrella sinistralis (Petit de la Saussaye, 1838)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.6084/m9.figshare.29924021.v1
title: Supplementary Material for: Team Based Pediatric Type 1 Diabetes Care in the US: Current Practices and Sustainability Concerns

description: Introduction: Multidisciplinary care can improve glycemic outcomes in individuals with type 1 diabetes (T1D). Yet, prior studies suggest limited utilization of team-based care and either no reimbursement or inadequate reimbursement for diabetes and nutritional education, mental health and social support as well as remote services. We sought to evaluate multidisciplinary care services offered by pediatric diabetes centers to understand whether current practices are sustainable. Methods: The Pediatric Endocrine Society Diabetes Special Interest Group collaborated with the T1DX- Quality Improvement Collaborative to survey US pediatric diabetes centers on care delivery practices and resources for new onset and ongoing care, introduction of technology and telehealth focusing on team-based approaches. Results: We analyzed responses from 31 centers, mostly academic, from 16 states and Washington DC representing all geographical regions providing care for 45,759 youth with T1D who had at least one visit in 2022. Most centers (74%) provided initial diabetes education in the inpatient setting using clinic-employed staff. The majority initiated CGMs at or close to diagnosis and offered insulin pump therapy within the first year. All but one center encouraged communication with diabetes teams between visits. Less than half of practices estimated that at least 50% of their youth with T1D received mental health services and assessments for social concerns annually. Telehealth was utilized by all centers. Many centers indicated suboptimal reimbursement, and 87% operated at a budget deficit. Discussion: Despite the commitment of pediatric diabetes centers to provide high quality multidisciplinary care, many youth with T1D may not receive the services as frequently as recommended. These services are often unreimbursed. We advocate for alternative reimbursement models for clinical workflows that support the delivery of individualized, multidisciplinary care aligned with best practices shown to improve clinical outcomes and quality of life for youth with T1D. Examples include expansion of telemedicine and remote monitoring, non-face-to-face acute and routine care, navigation of technology, supplies and services, engagement and coordination of community-based resources among others. Such models would promote equitable, needs-based care while enabling centers to operate efficiently.
DOI: 10.3535/0np-bee-9tk
title: Mangelia multilineolata (Deshayes, 1835)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/51b-fba-at4
title: Columbella fuscata G. B. Sowerby I, 1832

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/z7m-t0q-qyb
title: Nassarius comptus (A. Adams, 1852)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/7kx-rx8-hlg
title: Columbella rustica (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/yqw-sxl-8fw
title: Guraleus tasmanicus (Tenison Woods, 1876)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.6084/m9.figshare.29924024
title: Supplementary Material for: Dialysis, Antithrombotics, and Lesion Location: Who Benefits Most from Gel Immersion Endoscopy in Gastric Endoscopic Submucosal Dissection?

description: Introduction: Gel-immersion endoscopy (GIE) is a technique used to maintain a clear view during gastric endoscopic submucosal dissection (ESD). We aimed to identify cases most likely to benefit from GIE for ESD bleeding by reviewing our clinical experience and determining the associated factors. Methods: We retrospectively analyzed 470 lesions in 380 patients who underwent gastric ESD between October 2020 and March 2023. The patients were divided into conventional method (CM, n=433) and GIE groups (n=37). We compared the clinical and pathological characteristics between the groups. Univariate and multivariate logistic regression analyses were used to identify factors associated with GIE use. Among the GIE group, hemostasis times under gas, water, and gel conditions were compared using the Kruskal–Wallis test. Results: Multivariate analysis revealed that dialysis (odds ratio [OR]: 15.3), concurrent antiplatelet and anticoagulant use (OR: 9.5), and tumor location in the middle third (OR: 3.5), upper third (OR: 5.7), or remnant stomach (OR: 9.3) were independently associated with GIE use. No significant differences in overall hemostasis time were observed between gas, water, or gel. Of the nine bleeding events exceeding 300 s under gas immersion, seven achieved successful hemostasis by switching to GIE, with a median of 32 s to locate the source and 140 s to complete hemostasis. Conclusion: Dialysis, combined antithrombotic use, and certain tumor locations were key factors influencing GIE for ESD bleeding. Although the overall hemostasis times did not differ, GIE may be particularly beneficial in high-risk scenarios.
DOI: 10.6084/m9.figshare.29924024.v1
title: Supplementary Material for: Dialysis, Antithrombotics, and Lesion Location: Who Benefits Most from Gel Immersion Endoscopy in Gastric Endoscopic Submucosal Dissection?

description: Introduction: Gel-immersion endoscopy (GIE) is a technique used to maintain a clear view during gastric endoscopic submucosal dissection (ESD). We aimed to identify cases most likely to benefit from GIE for ESD bleeding by reviewing our clinical experience and determining the associated factors. Methods: We retrospectively analyzed 470 lesions in 380 patients who underwent gastric ESD between October 2020 and March 2023. The patients were divided into conventional method (CM, n=433) and GIE groups (n=37). We compared the clinical and pathological characteristics between the groups. Univariate and multivariate logistic regression analyses were used to identify factors associated with GIE use. Among the GIE group, hemostasis times under gas, water, and gel conditions were compared using the Kruskal–Wallis test. Results: Multivariate analysis revealed that dialysis (odds ratio [OR]: 15.3), concurrent antiplatelet and anticoagulant use (OR: 9.5), and tumor location in the middle third (OR: 3.5), upper third (OR: 5.7), or remnant stomach (OR: 9.3) were independently associated with GIE use. No significant differences in overall hemostasis time were observed between gas, water, or gel. Of the nine bleeding events exceeding 300 s under gas immersion, seven achieved successful hemostasis by switching to GIE, with a median of 32 s to locate the source and 140 s to complete hemostasis. Conclusion: Dialysis, combined antithrombotic use, and certain tumor locations were key factors influencing GIE for ESD bleeding. Although the overall hemostasis times did not differ, GIE may be particularly beneficial in high-risk scenarios.
DOI: 10.3535/3rk-z41-mrc
title: Buchema interstrigata (E. A. Smith, 1882)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/sg8-cmp-kn0
title: Olividae Latreille, 1825

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/kfc-ex2-4cz
title: Marginellidae J. Fleming, 1828

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/83p-baz-gbj
title: Megastomia conoidea (Brocchi, 1814)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/mcq-anf-fy2
title: Tritia mutabilis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/kl6-hxr-zw9
title: Heliacus areola (Gmelin, 1791)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/pdz-slk-f16
title: Leufroyia leufroyi (Michaud, 1828)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/h7e-w0m-tr2
title: Clavatula bimarginata (Lamarck, 1822)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/k72-mz7-1h7
title: Cancellaria reticulata (Linnaeus, 1767)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/njg-h0j-4zm
title: Olivella watermani T. L. McGinty, 1940

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/0hw-nfh-cfc
title: Bornia sebetia (O. G. Costa, 1830)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/rnf-35q-4p6
title: Dentimargo Cossmann, 1899

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/80s-xvd-4jg
title: Oliva vidua (Röding, 1798)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/ax1-m0n-v1d
title: Austromitra cinnamomea (A. Adams, 1855)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/9ea-4tm-a0z
title: Nassarius globosus (Quoy & Gaimard, 1833)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/g0m-mzk-6a4
title: Conus textile Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/44e-j3j-89e
title: Phrontis hotessieriana (A. d'Orbigny, 1842)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/tza-ya4-w0n
title: Mitrella moleculina (Duclos, 1840)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/0sd-9xs-r1p
title: Architectonica maxima (R. A. Philippi, 1849)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/pkt-jdx-1ts
title: Columbellidae Swainson, 1840

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/mkb-m3x-2f2
title: Conus stercusmuscarum Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.